Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jilin City
Clinical trial register · China

Clinical Trials in Jilin City, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19257 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:17 UTC
19257
Studies in scope
all four open statuses
11829
Recruiting now
open to new participants
2031
Lead sponsors
across recruiting studies
Top sites
Beijing 5598 Shanghai 3888 Guangzhou 3358 Hangzhou 1831 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 DualityBio Inc.2 Brise Pharmaceuticals Co., Ltd.2 Xi'an Xintong Pharmaceutical Research Co.,Ltd.2 Beijing Anzhen Hospital2 Ausper Biopharma Co., Ltd.2 Hongying Jiang, MD1 Air Force Military Medical University, China1 Cytokinetics1 The Children's Hospital of Zhejiang University School of Medicine1 Shanghai Dynaheart Medtech Co., Ltd.1 Xuanwu Hospital, Beijing1 Capital Medical University1 Peking Union Medical College Hospital1 Luye Pharma Group Ltd.1 Ottawa Heart Institute Research Corporation1 West China Hospital1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1 BioDlink Biopharm Co., Ltd.1 Peking University First Hospital1 Bisirna Therapeutics (Suzhou) Co., Ltd.1 Daiichi Sankyo1 AstraZeneca1 ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.1 Children's Hospital of Chongqing Medical University1 Show all 28
Site location
Beijing5598 Shanghai3888 Guangzhou3358 Hangzhou1831 Wuhan1343 Chengdu1309 Nanjing1213 Changsha1159 Chongqing1083 Fuzhou1042 Tianjin939 Zhengzhou928 Hefei906 Jinan791 Changchun640 Shenzhen585 Harbin549 Nanchang449 Xi'an443 Nanning442 Suzhou431 Shenyang406 Xiamen392 Shijiazhuang351 Lanzhou273 Show all 624
All 624 locations
Target enrolment
to

Trials with a site in Jilin City

34 of 19257 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Brise Pharmaceuticals Co., Ltd.
Phase 3
1,000
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-11-20
Not yet open
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Recruiting
Brise Pharmaceuticals Co., Ltd.
Phase 2/3
2,079
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-30
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
DrugAflibercept
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Recruiting
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Cangzhou, Dongguan, Foshan, Guiyang, Jilin City, Kunming, Tianjin, Tianshui
2026-08-01
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
DrugAHB-171
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Recruiting
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Not yet open
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Early Phase 1
94
Jilin City
2026-03-25
Recruiting
Beijing Anzhen Hospital
Not applicable
252
Beijing, Dalian, Jilin City, Nanchang, Shanghai
2026-02-26
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Not yet open
Hongying Jiang, MD
Not applicable
500
Beijing, Hunan, Guangxi, Jilin City, Henan
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Not yet open
Beijing Anzhen Hospital
Not applicable
792
Beijing, Dalian, Jilin City
2026-01
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Peking University First Hospital
Phase 2/3
300
Beijing, Shijiazhuang, Jilin City
2025-12-25
Recruiting
Capital Medical University
Not applicable
300
Hunan, Guangxi, Beijing, Jilin City, Henan
2025-10-01
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Active, closed
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Phase 2/3
1,444
Jilin City
2025-07-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
DrugsIndomethacin·Diclofenac
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression
NCT06920706Post-stroke Depression, Remote Ischemic Conditioning
Xuanwu Hospital, Beijing
Not applicable
240
Tongren, Baoding, Jilin City, Jincheng, Beijing
2025-04-10
Active, closed
Shanghai Dynaheart Medtech Co., Ltd.
Not applicable
254
Jilin City, Shanghai
2024-12-30
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
180
Jilin City
2024-12-13
Recruiting
Luye Pharma Group Ltd.
Phase 3
180
Jilin City
2024-09-14
Recruiting
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
A Trial of SHR-4849 in Advanced Solid Tumors
NCT06443489Advanced Solid Tumors
DrugSHR-4849
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
80
Jilin City
2024-06-26
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Active, closed
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Active, closed
Cytokinetics
Phase 3
500
Guangzhou, Beijing, Jilin City, Nanjin, Shanghai, Shenyang, Wuhan, Xi'an
2023-08-31
Recruiting
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT05427370Coronary Artery Disease, Heart Failure Systolic
Sunnybrook Health Sciences Centre
Not applicable
754
Jilin City, Shanghai
2023-06-22
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
144
Jilin City
2022-09-20
Active, closed
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Active, closed
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
Ottawa Heart Institute Research Corporation
Not applicable
176
Jilin City
2018-09-01
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-china/city/jilin-city

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,257 studies in total at the last sync on 13 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Jilin City.

How many clinical trials are recruiting in Jilin City?

18 of the 34 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jilin City), 34 studies
PhaseStudiesRecruitingShare
Not applicable11632.4%
Phase 38123.5%
Phase 14311.8%
Phase 24411.8%
Phase 2/3328.8%
Phase 1/2225.9%
Early Phase 1102.9%
Phase 4102.9%

Most active sponsors

Lead sponsors with the most studies (Jilin City)
Lead sponsorStudiesRecruiting
Ausper Biopharma Co., Ltd.22
Beijing Anzhen Hospital21
Brise Pharmaceuticals Co., Ltd.21
DualityBio Inc.21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.22
Xi'an Xintong Pharmaceutical Research Co.,Ltd.20
Air Force Military Medical University, China11
AstraZeneca10
BioDlink Biopharm Co., Ltd.10
Bisirna Therapeutics (Suzhou) Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.